Published works by Nicole M. DeAbrantes

Published works

• PTAB Finds Another Patent Fails to Pass Muster Under 101

  PTAB Law Blog · November 11, 2024

  LEX-WK-39RK65MT
• Federal Circuit Precedential Opinion Sheds Light on Importance of Issues Presented On Appeal

  PTAB Law Blog · April 27, 2023

  LEX-WK-YZQ1PAK8
• Just Skinny Enough: District Court Dismisses Inducement Claims Against Generic “Skinny Label”

  Biosimilars Law Bulletin · January 20, 2022

  LEX-WK-6JS4N3J1
• The Federal Circuit Finds IPR Petitioner Has Standing

  PTAB Law Blog · January 16, 2022

  LEX-WK-A7N56NN7
• Federal Circuit Panel Rehears Skinny Label Case (<i>GSK v. Teva</i>)

  Biosimilars Law Bulletin · March 1, 2021

  LEX-WK-1KXJY19N
• Federal Circuit Grants Remand in Ex Parte Reexam While World Waits for Supreme Court to Weigh in on Arthrex

  PTAB Law Blog · June 29, 2020

  LEX-WK-5R6BRDQE
• Delays, Denials and Uncertainty: Developments in the <i>Arthrex</i> Redo Case Line

  PTAB Law Blog · June 1, 2020

  LEX-WK-FT7ZHN8Q
• The Federal Circuit Dismisses Pfizer’s Appeal for Lack of Standing

  Biosimilars Law Bulletin · May 11, 2020

  LEX-WK-YG1BMMY4
• Committee for Medicinal Products for Human Use Provides Biosimilar Updates at March Meeting

  Biosimilars Law Bulletin · April 21, 2020

  LEX-WK-AW580AQN
• Hospira Requests <i>En Banc</i> Review of Ruling Regarding Safe Harbor

  Biosimilars Law Bulletin · February 14, 2020

  LEX-WK-AN2A6CX7
• Federal Circuit Upholds Panel’s Noninfringement Ruling in Amgen v. Sandoz Appeal

  Biosimilars Law Bulletin · September 11, 2019

  LEX-WK-AN5YWK4G
• Retroactive Application of IPRs to Pre-AIA Patents Does Not Violate the Takings Clause

  PTAB Law Blog · August 30, 2019

  LEX-WK-6J7BRR81
• PTAB Modifies FWD Over Construction of Term “Non-Aerobic Conditions”

  Biosimilars Law Bulletin · June 5, 2019

  LEX-WK-6GTNK0JV
• “Competitor Standing” Not Sufficient to Establish Article III Standing for Appeal of PTAB Decision

  PTAB Law Blog · May 30, 2019

  LEX-WK-ZCT21357
• PGR Instituted for Protein Refolding Patent

  Biosimilars Law Bulletin · May 16, 2019

  LEX-WK-YDPYBFBX
• Overly Broad Challenges May Lead PTAB to Deny Institution

  PTAB Law Blog · February 14, 2019

  LEX-WK-AJBQR3M6
• PTAB’s Interpretation of “Same or Substantially the Same Prior Art” Under §325(d)

  PTAB Law Blog · September 20, 2018

  LEX-WK-YBS1J00Y
• New Proposed Legislation: The Hatch-Waxman Integrity Act of 2018

  Biosimilars Law Bulletin · July 3, 2018

  LEX-WK-THPCRBHD
• Motions for Additional Discovery at the PTAB

  PTAB Law Blog · June 25, 2018

  LEX-WK-6W9V4Z2K
• PTAB Denies Another IPR Petition Relating to Adalimumab

  Biosimilars Law Bulletin · June 14, 2018

  LEX-WK-CDHFKHBP
• Federal Circuit Holds That PTAB May Issue Adverse Judgments Prior to an Institution Decision

  PTAB Law Blog · February 6, 2018

  LEX-WK-DDBWK85F
• Amicus Brief Filed By Biopharmaceutical Companies in Support of Amgen’s Petition for Rehearing <i>En Banc</i>

  Biosimilars Law Bulletin · January 22, 2018

  LEX-WK-26VMBFG2
• Standing Questioned Before the Federal Circuit in <i>Momenta Pharms. v. Bristol-Myers Squibb Co.</i>

  Biosimilars Law Bulletin · January 5, 2018

  LEX-WK-RH1EGRR3
• Supreme Court Oral Argument in <i>Oil States</i>

  PTAB Law Blog · December 12, 2017

  LEX-WK-XGKW86GH
• The Potential Impact of the Supreme Court’s Decision in <i>Oil States</i>

  PTAB Law Blog · November 22, 2017

  LEX-WK-SZ5MAQDH